Company Performance Metrics
- Daniela Pacheco: Co-founder & CTOPast Role: 3B’s Research Group, Researcher
- Sebastião van Uden: Co-founder & CEOPast Role: Bioengineering Laboratories, Marie Curie Fellow
Unlocking the Full Power of Microbiota Bac3Gel is a deep-tech biotechnology company revolutionizing microbiota research and applications through its innovative biomaterials and culture systems. Its proprietary technology enables the cultivation, analysis, and harnessing of microbiota in a way that was previously impossible, bridging critical gaps
in preclinical research, biotech production, and future therapeutic development.
Technology & Core Innovation Bac3Gel’s platform is built around a tailorable biomimetic system that provides microbiota with the precise microenvironmental conditions they need to thrive. Unlike conventional in vitro culture methods, Bac3Gel’s system mimics natural microbiota habitats, allowing researchers and biotech companies to work with complex microbial ecosystems in a reproducible and scalable manner.
Bac3Gel’s biomaterials are: Ready-to-use – no complex setup required, Customizable – adaptable to different microbial ecosystems, Biomimetic – replicates key physiological conditions of native microbiota environments, Scalable – suitable for both small-scale research and industrial applications, Ethical & Sustainable – reducing the need for animal models.
Products & Applications
1. Microbiota Culturing - Ready-to-use In-vitro Mucus Models Bac3Gel offers advanced mucus-like matrices that replicate the native conditions of various human body sites, enabling high-throughput screening, microbiota research, and drug discovery. These models are compatible with: Gut microbiota studies, Gastric and intestinal research, Cervico-vaginal microbiome studies, Lung and respiratory microbiota analysis, Microfluidic and high-throughput applications.
2. Growth Enhancer Beads These proprietary microbeads are designed to boost the proliferation of hard-to-culture microbes, unlocking new possibilities in microbiome-based therapeutics, probiotics, and industrial microbiology. - Compatible with bioreactors – scalable for industrial applications. - Enhances microbiota growth – especially beneficial for strict anaerobes and difficult-to-culture strains. - Facilitates microbial metabolite extraction – enabling biotechnology applications. - Increases production yield – improving efficiency in biotech and pharmaceutical production.
Future Vision: 2026: Expand into microbiome-based health and supplement markets. 2029-2030: Develop next-generation biotherapeutics leveraging microbiota ecosystems.
